echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Pfizer's new crown oral drug clinically successfully neutralizes antibodies and vaccine stocks fall again across the board

    Pfizer's new crown oral drug clinically successfully neutralizes antibodies and vaccine stocks fall again across the board

    • Last Update: 2021-12-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, new crown oral drugs have continued to usher in good news


    On November 4, Merck announced that its new crown oral drug Molnupiravir was approved in the UK for the treatment of mild to moderate new crown pneumonia


    On November 5, Pfizer followed suit and announced that its new oral drug Paxlovid in the Phase 2/3 clinical EPIC-HR study interim analysis reduced hospitalization or mortality by 89%


    From: Pfizer official website

    Vaccine stocks and neutralizing antibody concept stocks once again fell across the board following the positive development of oral drugs


    Vaccine stocks share price changes in the past 5 days

    Moderna is the vaccine stock that has suffered the most recently


    With turbulence on the new crown track, Pfizer has undoubtedly become a true leader, achieving dual coverage of vaccines and oral drugs


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.